Memorial Sloan Kettering Cancer Center is recruiting patients for a PHASE1 clinical trial testing pembrolizumab (Keytruda) for mesothelioma.
The trial, designated NCT04897022, aims to enroll up to 14 participants at 7 sites, including locations in New Jersey, New York.
About the Study
The purpose of this study is to find out whether IMPRINT in combination with pembrolizumab is a safe treatment for people with malignant pleural mesothelioma (MPM).The highest dose of IMPRINT that causes few or mild side effects when given in combination with pembrolizumab will be found. Once the highest safe dose of IMPRINT is found, it will be tested in combination with pembrolizumab in future participants to see whether the combination may be an effective treatment for MPM.
Treatment Approach
This trial uses a PD-1 checkpoint inhibitor that helps the immune system recognize and attack cancer cells.
Key trial details:
- Phase: PHASE1
- Sponsor: Memorial Sloan Kettering Cancer Center
- Enrollment target: 14
- Status: RECRUITING
Why This Trial Matters
Memorial Sloan Kettering is one of the leading mesothelioma treatment centers in the United States.
Study Locations
The trial is recruiting at:
- Memorial Sloan Kettering Basking Ridge (Limited protocol activities), New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), New Jersey
- Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities), New York
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), New York
How to Enroll
Patients interested in this trial should:
- Discuss eligibility with their oncologist
- Review the full eligibility criteria on ClinicalTrials.gov
- Contact the study coordinator for screening